Novo Nordisk’s shares slump after lowered outlook and louder competition headlines, but the business still leads a growing diabetes and weight-loss market with new treatments on the way. The key question is whether today’s worries around pricing pressure, copycat drugs, and a heavy reliance on one blockbuster are truly lasting—or just masking a stronger long-term story.Read more